Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...
In a report released on January 30, Florian Treisch from Kepler Capital maintained a Buy rating on Sage Group plc (SGE – Research Report), ...
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...
Sage Group PLC hit a new 52-week high, surpassing its previous peak of £13.42, which the company reached on January 22nd.
Jefferies raised the firm’s price target on Sage Group (SGPYY) to 1,600 GBp from 1,500 GBp and keeps a Buy rating on the shares. The “most ...
3don MSN
Research photo from the National Cancer Institute, shared via Unsplash. (NCI Photo) When Luca Foschini, head of Seattle's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback